Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial.
Basset-Séguin N, Hauschild A, Kunstfeld R, Grob J, Dréno B, Mortier L, Ascierto PA, Licitra L, Dutriaux C, Thomas L, Meyer N, Guillot B, Dummer R, Arenberger P, Fife K, Raimundo A, Dika E, Dimier N, Fittipaldo A, Xynos I, Hansson J. Basset-Séguin N, et al. Among authors: dimier n. Eur J Cancer. 2017 Nov;86:334-348. doi: 10.1016/j.ejca.2017.08.022. Epub 2017 Nov 5. Eur J Cancer. 2017. PMID: 29073584 Free article. Clinical Trial.
Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study.
Sekulic A, Migden MR, Basset-Seguin N, Garbe C, Gesierich A, Lao CD, Miller C, Mortier L, Murrell DF, Hamid O, Quevedo JF, Hou J, McKenna E, Dimier N, Williams S, Schadendorf D, Hauschild A; ERIVANCE BCC Investigators. Sekulic A, et al. Among authors: dimier n. BMC Cancer. 2017 May 16;17(1):332. doi: 10.1186/s12885-017-3286-5. BMC Cancer. 2017. PMID: 28511673 Free PMC article. Clinical Trial.
Assessment of quality of life using Skindex-16 in patients with advanced basal cell carcinoma treated with vismodegib in the STEVIE study.
Hansson J, Bartley K, Karagiannis T, Grob JJ, Kunstfeld R, Dréno B, Mortier L, Ascierto PA, Licitra L, Dutriaux C, Thomas L, Meyer N, Guillot B, Dummer R, Fife K, Ernst DS, Yim YM, Dimier N, Fittipaldo A, Basset-Séguin N, Hauschild A. Hansson J, et al. Among authors: dimier n. Eur J Dermatol. 2018 Dec 1;28(6):775-783. doi: 10.1684/ejd.2018.3448. Eur J Dermatol. 2018. PMID: 30698147 Clinical Trial.
Correction to: Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study.
Sekulic A, Migden MR, Basset-Seguin N, Garbe C, Gesierich A, Lao CD, Miller C, Mortier L, Murrell DF, Hamid O, Quevedo JF, Hou J, McKenna E, Dimier N, Williams S, Schadendorf D, Hauschild A; ERIVANCE BCC Investigators. Sekulic A, et al. Among authors: dimier n. BMC Cancer. 2019 Apr 18;19(1):366. doi: 10.1186/s12885-019-5568-6. BMC Cancer. 2019. PMID: 30999949 Free PMC article.
A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis.
Couban S, Benevolo G, Donnellan W, Cultrera J, Koschmieder S, Verstovsek S, Hooper G, Hertig C, Tandon M, Dimier N, Malhi V, Passamonti F. Couban S, et al. Among authors: dimier n. J Hematol Oncol. 2018 Sep 24;11(1):122. doi: 10.1186/s13045-018-0661-x. J Hematol Oncol. 2018. PMID: 30249277 Free PMC article. Clinical Trial.
Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.
Sehn LH, Chua N, Mayer J, Dueck G, Trněný M, Bouabdallah K, Fowler N, Delwail V, Press O, Salles G, Gribben J, Lennard A, Lugtenburg PJ, Dimier N, Wassner-Fritsch E, Fingerle-Rowson G, Cheson BD. Sehn LH, et al. Among authors: dimier n. Lancet Oncol. 2016 Aug;17(8):1081-1093. doi: 10.1016/S1470-2045(16)30097-3. Epub 2016 Jun 23. Lancet Oncol. 2016. PMID: 27345636 Clinical Trial.
Safety and efficacy of vismodegib in relapsed/refractory acute myeloid leukaemia: results of a phase Ib trial.
Bixby D, Noppeney R, Lin TL, Cortes J, Krauter J, Yee K, Medeiros BC, Krämer A, Assouline S, Fiedler W, Dimier N, Simmons BP, Riehl T, Colburn D. Bixby D, et al. Among authors: dimier n. Br J Haematol. 2019 May;185(3):595-598. doi: 10.1111/bjh.15571. Epub 2018 Sep 11. Br J Haematol. 2019. PMID: 30203489 Free article. Clinical Trial. No abstract available.
Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone.
Cheson BD, Trask PC, Gribben JG, Dimier N, Kimby E, Lugtenburg PJ, Thieblemont C, Wassner-Fritsch E, Launonen A, Sehn LH. Cheson BD, et al. Among authors: dimier n. Ann Hematol. 2017 Feb;96(2):253-259. doi: 10.1007/s00277-016-2878-5. Epub 2016 Nov 30. Ann Hematol. 2017. PMID: 27900446 Free PMC article. Clinical Trial.
Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial.
Hutchings M, Morschhauser F, Iacoboni G, Carlo-Stella C, Offner FC, Sureda A, Salles G, Martínez-Lopez J, Crump M, Thomas DN, Morcos PN, Ferlini C, Bröske AE, Belousov A, Bacac M, Dimier N, Carlile DJ, Lundberg L, Perez-Callejo D, Umaña P, Moore T, Weisser M, Dickinson MJ. Hutchings M, et al. Among authors: dimier n. J Clin Oncol. 2021 Jun 20;39(18):1959-1970. doi: 10.1200/JCO.20.03175. Epub 2021 Mar 19. J Clin Oncol. 2021. PMID: 33739857 Free PMC article. Clinical Trial.
20 results